Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2021-04-30

Clinical Trial Update: Comparative Analysis of Outcomes Among Patients Treated With Xeljanz vs Biologics

View source ↗

Summary

A completed clinical trial comparing outcomes of Xeljanz with biologics in patients with rheumatoid arthritis.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • XELJANZ (tofacitinib)

Snippet

Sponsor: Pfizer | Conditions: Arthritis, Rheumatoid | Status: COMPLETED | Results posted: 2021-04-30